MolecularMD
Icon Acquires MolecularMD
MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.
FDA CDx Class Labeling Draft Guidance May Ease Patient Access, Spur Competition Among Test Makers
Premium
The draft guidelines have intrigued industry players interested in pursuing labeling that would allow their CDx to direct treatment for a class of drugs instead of one drug.
Sysmex, MolecularMD to Collaborate for CDx Development, Commercialization
The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.
Health Canada Approves Two BCR-ABL Tests
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
In Brief This Week: Agendia and MolecularMD
Agendia said this week that US Oncology has joined its FLEX breast cancer registry study.